Bruce AJ Ponder

Introduction The 1990s were a ‘decade mirabilis’ when it came to the discovery of tumour suppressor genes: NF1 in 1990, APC in 1991, vHL in 1993, BRCA1 in 1994, BRCA2 in 1995 and PTEN in 1997. In that decade, these genes were also linked to clinically characterised hereditary cancer syndromes: neurofibromatosis type 1, von Hippel–Lindau, familial polyposis coli, hereditary breast cancer and Cowden syndrome. In 1993, two articles published in Nature and Human Molecular Genetics (Donis-Keller et al.

AbstractTwo opposing clusters of transcription factors (TF) have been associated with the differential risks of estrogen receptor positive or negative breast cancers, but the mechanisms underlying the opposing functions of the two clusters are undefined. In this study, we identified NFIB and YBX1 as novel interactors of the estrogen receptor alpha (ESR1). NFIB and YBX1 are both risk TF associated with progression of ESR1-negative disease.